Sort   by:  
 Page size 
TranscriptomicsTranscriptional profiles of Campylobacter jejuni macrolide resistant strain JL272 to 4mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni 
2013-10-10 | E-GEOD-43025 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni NCTC 11168 to 4mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 
2013-10-10 | E-GEOD-43023 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiles of Campylobacter jejuni NCTC 11168 to 0.125mg/L erythromycin treatment
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying CampylobacterM-bM-^@M-^...
ORGANISM(S): Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 
2013-10-10 | E-GEOD-43024 | biostudies-arrayexpress
Sort   by:  
 Page size